

Log in



CLINICAL RESEARCH STUDY | VOLUME 136, ISSUE 3, P294-301.E2, MARCH 2023


The Effects of Human Papillomavirus Infection and Vaccination on Cardiovascular Diseases, NHANES 2003-2016

Xiaopeng Liang, MD • Oscar Hou In Chou, MSc • Bernard M.Y. Cheung, MB, BChir, PhD   •[Show footnotes](#)Published: October 14, 2022 • DOI: <https://doi.org/10.1016/j.amjmed.2022.09.021> • PlumX Metrics

Abstract

Background

Human papillomavirus (HPV) infection has been proposed to be an unconventional risk factor for cardiovascular diseases. We investigated the association between HPV infection and cardiovascular diseases among women with or without HPV vaccination.



This cross-sectional study included 9,353 women aged between 20 to 59 years old who were tested for vaginal HPV DNA in the National Health and Nutrition Examination Survey (NHANES) 2003-2016. Cardiovascular diseases were defined as the presence of self-reported coronary heart diseases, heart attacks, angina pectoris, and stroke. The association between HPV and cardiovascular diseases was studied using logistic regression, with adjustment for the potential confounders.

Results

A total of 40.8% of women were HPV DNA positive; 3.0% had cardiovascular diseases; and 9.0% of women received the HPV vaccine. The presence of vaginal HPV infection was associated with cardiovascular diseases (odd ratio [OR] = 1.66, 95% confidence interval [CI] 1.28-2.16), which remained significant (OR = 1.54, 95% CI 1.15-2.08) after adjustment for sociodemographic characteristics, lifestyle behaviors, medical history, family history of cardiovascular diseases, and antihypertensive drugs. The association was absent among those who were vaccinated against HPV (OR= 0.50, 95% CI 0.07-3.51) but present among those who were not (OR = 1.63, 95% CI 1.18-2.25).

Conclusions

There was an association between HPV infection and cardiovascular diseases. This association was not significant among women vaccinated against HPV. The effect of HPV vaccination on cardiovascular diseases requires further investigation.

Keywords

[Cardiovascular diseases](#) • [Coronary heart diseases](#) • [Human papillomavirus infection](#) • [HPV vaccination](#) • [Vaccination](#)

Abbreviations:

[ACE](#) (Angiotensin-converting enzyme), [ARB](#) (Angiotensin II receptor blocker), [CI](#) (Confidence intervals), [HPV](#) (Human papillomavirus), [ITR](#) (InflammoThrombotic Response), [NHANES](#) (National Health and Nutrition Examination Survey), [OR](#) (Odds ratio), [SARS-CoV-2](#) (Severe respiratory syndrome coronavirus 2)



To read this article in full you will need to make a payment

Purchase one-time access:

Academic & Personal: 24 hour online access

Corporate R&D Professionals: 24 hour online access

► One-time access price info

Subscribe:

Subscribe to *The American Journal of Medicine*

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

References

1. **Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.**

Lancet. 2017; **390**: 1151-1210

[https://doi.org/10.1016/s0140-6736\(17\)32152-9](https://doi.org/10.1016/s0140-6736(17)32152-9)

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)



acMahon S • Peto R • Cutler J • et al.

ood pressure, stroke, and coronary heart disease. Part 1, Prolonged dif



blood pressure: prospective observational studies corrected for the regression dilution bias.

Lancet. 1990; **335**: 765-774

[https://doi.org/10.1016/0140-6736\(90\)90878-9](https://doi.org/10.1016/0140-6736(90)90878-9)

[View in Article](#) ^

[Scopus \(3888\)](#) • [PubMed](#) • [Abstract](#) • [Google Scholar](#)

3. Jagannathan R • Patel SA • Ali MK • Narayan KMV.

Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors.

Curr Diab Rep. 2019; **19**: 44

<https://doi.org/10.1007/s11892-019-1161-2>

[View in Article](#) ^

[Scopus \(107\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

4. Cheung BM • Lauder IJ • Lau CP • Kumana CR.

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.

Br J Clin Pharmacol. 2004; **57**: 640-651

<https://doi.org/10.1111/j.1365-2125.2003.02060.x>

[View in Article](#) ^

[Scopus \(242\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

5. Ong KL • Tso AW • Lam KS • Cheung BM.

Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension.

Hypertension. 2008; **51**: 1142-1148

<https://doi.org/10.1161/hypertensionaha.107.105205>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)



6. Khot UN • Khot MB • Bajzer CT • et al.
Prevalence of conventional risk factors in patients with coronary heart disease.
JAMA. 2003; **290**: 898-904
<https://doi.org/10.1001/jama.290.7.898>
[View in Article](#) ^
[Scopus \(1154\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

7. Fleming RM
The pathogenesis of vascular disease.
in: Chang JB Textbook of Angiology. Springer, New York, NY2000: 787-798


[View in Article](#) ^
[Crossref](#) • [Google Scholar](#)

8. Fleming RM • Fleming MR
FMTVDM quantitative nuclear imaging finds three treatments for SARS-CoV-2.
Biomed J Sci & Tech Res. 2021; **33**: 26041-26083
<https://doi.org/10.26717/BJSTR.2021.33.005443>

[View in Article](#) ^
[Crossref](#) • [Google Scholar](#)

9. Schiffman M • Castle PE • Jeronimo J • Rodriguez AC • Wacholder S.
Human papillomavirus and cervical cancer.
Lancet. 2007; **370**: 890-907
[https://doi.org/10.1016/s0140-6736\(07\)61416-0](https://doi.org/10.1016/s0140-6736(07)61416-0)

[View in Article](#) ^
[Scopus \(0\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

10. Shen Y • Xia J • Li H • Xu Y • Xu S.
Human papillomavirus infection rate, distribution characteristics, and risk of age in e- and postmenopausal women.
 *IC Womens Health*. 2021; **21**: 80



<https://doi.org/10.1186/s12905-021-01217-4>

[View in Article](#) ^

[Scopus \(6\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

11. Kuo HK • Fujise K.

Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006.

J Am Coll Cardiol. 2011; **58**: 2001-2006

<https://doi.org/10.1016/j.jacc.2011.07.038>

[View in Article](#) ^

[Scopus \(39\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

12. Brito LMO • Brito HO • Corrêa R • et al.

Human papillomavirus and coronary artery disease in climacteric women: is there an association?.

ScientificWorldJournal. 2019; 1872536

<https://doi.org/10.1155/2019/1872536>

[View in Article](#) ^

[Scopus \(6\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

13. Lawson JS • Glenn WK • Tran DD • Ngan CC • Dufrou JA • Whitaker NJ.

Identification of human papilloma viruses in atheromatous coronary artery disease.

Front Cardiovasc Med. 2015; **2**: 17

<https://doi.org/10.3389/fcvm.2015.00017>

[View in Article](#) ^


[Scopus \(26\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

14. Lowy DR.

HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.



Clin Invest. 2016; **126**: 5-11



<https://doi.org/10.1172/jci85446>

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

15. Hirth J.

Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature.

Hum Vaccin Immunother. 2019; **15**: 146-155

<https://doi.org/10.1080/21645515.2018.1512453>

[View in Article](#) ^

[Scopus \(80\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

16. Centers for Disease Control and Prevention (CDC)

National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data.

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD2016 (Available at:)

<https://www.cdc.gov/nchs/nhanes/index.htm>

(Accessed Nov 20, 2021)

[View in Article](#) ^

[Google Scholar](#)

17. Butler L • Popkin BM • Poti JM.

Associations of alcoholic beverage consumption with dietary intake, waist circumference, and body mass index in US adults: National Health and Nutrition Examination Survey 2003-2012.

J Acad Nutr Diet. 2018; **118**: 409-420.e3

<https://doi.org/10.1016/j.jand.2017.09.030>

[View in Article](#) ^

[Scopus \(24\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)



18. Strath SJ • Kaminsky LA • Ainsworth BE • et al.

Guide to the assessment of physical activity: clinical and research applications: a scientific statement from the American Heart Association.

Circulation. 2013; **128**: 2259-2279

<https://doi.org/10.1161/01.cir.0000435708.67487.da>

[View in Article](#) ^

[Scopus \(598\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Circulation. 2002; **106**: 3143-3421

[View in Article](#) ^

[Scopus \(11288\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

20. Whelton PK • Carey RM • Aronow WS • et al.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.

Hypertension. 2018; **71**: 1269-1324

<https://doi.org/10.1161/hyp.0000000000000066>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

21. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Health and Nutrition Examination Survey (NHANES). Laboratory procedure manual human papillomavirus (HPV) genotypes. Available

<https://wwwn.cdc.gov/nchs/data/nhanes/2015-2016/labmethods>



[PVSUR_I_HPVS_I_R_MET.pdf](#). Accessed Nov 20, 2021.



[View in Article](#) 

[Google Scholar](#)

22. Joo EJ • Chang Y • Kwon MJ • Cho A • Cheong HS • Ryu S.
High-risk human papillomavirus infection and the risk of cardiovascular disease in Korean women.

Circ Res. 2019; **124**: 747-756

<https://doi.org/10.1161/circresaha.118.313779>

[View in Article](#) 

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

23. Paavonen J • Jenkins D • Bosch FX • et al.
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Lancet. 2007; **369**: 2161-2170

[https://doi.org/10.1016/s0140-6736\(07\)60946-5](https://doi.org/10.1016/s0140-6736(07)60946-5)

[View in Article](#) 

[Scopus \(0\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

24. Joura EA • Giuliano AR • Iversen OE • et al.
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

N Engl J Med. 2015; **372**: 711-723

<https://doi.org/10.1056/NEJMoa1405044>

[View in Article](#) 

[Scopus \(927\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

25. Carozzi F • Puliti D • Ocello C • et al.
Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.

 *AC Infect Dis.* 2018; **18**: 38



<https://doi.org/10.1186/s12879-018-2945-8>

[View in Article](#) ^

[Scopus \(23\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

26. Paavonen J • Naud P • Salmerón J • et al.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Lancet. 2009; **374**: 301-314

[https://doi.org/10.1016/s0140-6736\(09\)61248-4](https://doi.org/10.1016/s0140-6736(09)61248-4)

[View in Article](#) ^

[Scopus \(0\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

27. Zhang Z • Zhang J • Xia N • Zhao Q.

Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.

Hum Vaccin Immunother. 2017; **13**: 2280-2291

<https://doi.org/10.1080/21645515.2017.1346755>

[View in Article](#) ^

[Scopus \(15\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

28. Avni-Singer LR • Yakely A • Sheth SS • Shapiro ED • Niccolai LM • Oliveira CR.

Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.

Public Health. 2020; **178**: 137-150

<https://doi.org/10.1016/j.puhe.2019.08.010>

[View in Article](#) ^

[Scopus \(5\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

arkowitz LE • Liu G • Hariri S • Steinau M • Dunne EF • Unger ER.



ivalence of HPV after introduction of the vaccination program in the Ur



Pediatrics. 2016; **137**e20151968

<https://doi.org/10.1542/peds.2015-1968>

[View in Article](#) ^

[Scopus \(233\)](#) • [Crossref](#) • [Google Scholar](#)

30. Rosenblum HG • Lewis RM • Gargano JW • Querec TD • Unger ER • Markowitz LE.

Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine - United States, 2003-2018.

MMWR Morb Mortal Wkly Rep. 2021; **70**: 415-420

<https://doi.org/10.15585/mmwr.mm7012a2>

[View in Article](#) ^

[Scopus \(30\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

31. Füle T • Máthé M • Suba Z • et al.

The presence of human papillomavirus 16 in neural structures and vascular endothelial cells.

Virology. 2006; **348**: 289-296

<https://doi.org/10.1016/j.virol.2005.12.043>

[View in Article](#) ^

[Scopus \(25\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

32. Foresta C • Bertoldo A • Garolla A • et al.

Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during HPV-16 semen infection.

BMC Infect Dis. 2013; **13**: 593

<https://doi.org/10.1186/1471-2334-13-593>

[View in Article](#) ^

[Scopus \(42\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

Atherosclerosis is an inflammatory disease.

Am Heart J. 1999; **138**: S419-S420

[https://doi.org/10.1016/s0002-8703\(99\)70266-8](https://doi.org/10.1016/s0002-8703(99)70266-8)

[View in Article](#) ^

[Scopus \(1197\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

34. Kovacic MB • Katki HA • Kreimer AR • Sherman ME.

Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections.

Hum Pathol. 2008; **39**: 1088-1095

<https://doi.org/10.1016/j.humphath.2007.12.002>

[View in Article](#) ^

[Scopus \(17\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

35. Bonin LR • Madden K • Shera K • et al.

Generation and characterization of human smooth muscle cell lines derived from atherosclerotic plaque.

Arterioscler Thromb Vasc Biol. 1999; **19**: 575-587

<https://doi.org/10.1161/01.atv.19.3.575>

[View in Article](#) ^

[PubMed](#) • [Crossref](#) • [Google Scholar](#)

36. Federico A • Morgillo F • Tuccillo C • Ciardiello F • Loguercio C.

Chronic inflammation and oxidative stress in human carcinogenesis.

Int J Cancer. 2007; **121**: 2381-2386

<https://doi.org/10.1002/ijc.23192>

[View in Article](#) ^

[Scopus \(735\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

byn M • Verdoodt F • Snijders PJ • et al.



Accuracy of human papillomavirus testing on self-collected versus clinic



samples: a meta-analysis.

Lancet Oncol. 2014; **15**: 172-183

[https://doi.org/10.1016/s1470-2045\(13\)70570-9](https://doi.org/10.1016/s1470-2045(13)70570-9)

[View in Article](#) ^

[PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

Article info

Publication history

Published online: October 14, 2022

Footnotes

Funding: None.

Conflicts of Interest: None.

Authorship: All authors had access to the data and a role in writing this manuscript.

Identification

DOI: <https://doi.org/10.1016/j.amjmed.2022.09.021>

Copyright

© 2022 Elsevier Inc. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles



Home	CENTERS	Academy	Contacts	Press Releases
ARTICLES AND ISSUES	Reducing Global Perioperative Risk	Submission Process	Editorial Board	AAIM
Articles In Press	FOR AUTHORS	Submit Your Manuscript	E B Conflict of Interest	Information
Current Issue	FOR AUTHORS		Information for Advertisers	AAIM Website
List of Issues	About Open Access	JOURNAL INFO		GREEN JOURNAL BLOG
Supplements	Guide to Authors	About Open Access	Permissions	FOLLOW US
Diagnostic Dilemma	Permissions	About the Journal/Journal Vision	Pricing	Facebook
Neurology Series	New Content Alerts		Reprints	Twitter
RESOURCE	Researcher	Career Opportunities	IN THE NEWS	YouTube

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the **Cookie settings | Your Privacy Choices** for this site.

Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

[Privacy Policy](#) [Terms and Conditions](#) [Accessibility](#) [Help & Contact](#)

